Fortress Biotech, Inc. Cost of Revenue
Fortress Biotech, Inc. (FBIO) reported Cost of Revenue of $6.14 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement
us-gaap:CostOfGoodsAndServicesSold · last filed 2026-08-13
- Fortress Biotech, Inc. cost of goods and services sold for the quarter ending 2026-06-30 was $6.14M, a 24.38% increase year-over-year.
- Fortress Biotech, Inc. cost of goods and services sold for the quarter ending 2026-03-31 was $6.22M, a 29.81% increase year-over-year.
- Fortress Biotech, Inc. cost of goods and services sold for the quarter ending 2025-12-31 was $5.44M, a 16.24% increase year-over-year.
- Fortress Biotech, Inc. cost of goods and services sold for the quarter ending 2025-09-30 was $5.75M, a 28.72% increase year-over-year.
- Fortress Biotech, Inc. cost of goods and services sold for fiscal 2025 was $20.92M, a 0.22% increase from fiscal 2024.
- Fortress Biotech, Inc. cost of goods and services sold for fiscal 2024 was $20.88M, a 8.80% decline from fiscal 2023.
- Fortress Biotech, Inc. cost of goods and services sold for fiscal 2023 was $22.89M, a 25.61% decline from fiscal 2022.
- Fortress Biotech, Inc. cost of goods and services sold for fiscal 2022 was $30.77M, a 4.08% decline from fiscal 2021.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 3 month as first filed | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 6 month as first filed | Cost of Goods and Services Sold 9 month | Cost of Goods and Services Sold 9 month as first filed | Cost of Goods and Services Sold 12 month | Cost of Goods and Services Sold 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $6.14M 10-Q · filed 2026-08-13 | $12.36M 10-Q · filed 2026-08-13 | $17.80M derived: sum of 3 quarters · filed 2026-08-13 | $23.56M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2026-03-31 | $6.22M 10-Q · filed 2026-05-14 | $11.66M derived: sum of 2 quarters · filed 2026-05-14 | $17.41M derived: sum of 3 quarters · filed 2026-05-14 | $22.35M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-12-31 | $5.44M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $11.20M derived: sum of 2 quarters · filed 2026-03-31 | $16.13M derived: sum of 3 quarters · filed 2026-08-13 | $20.92M 10-K · filed 2026-03-31 | ||||
| 2025-09-30 | $5.75M 10-Q · filed 2025-11-14 | $10.69M derived: sum of 2 quarters · filed 2026-08-13 | $15.48M 10-Q · filed 2025-11-14 | $20.16M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-06-30 | $4.94M 10-Q · filed 2026-08-13 | $9.73M 10-Q · filed 2026-08-13 | $14.41M derived: sum of 3 quarters · filed 2026-08-13 | $18.88M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-03-31 | $4.79M 10-Q · filed 2026-05-14 | $9.47M derived: sum of 2 quarters · filed 2026-05-14 | $13.94M derived: sum of 3 quarters · filed 2026-05-14 | $19.67M derived: sum of 4 quarters · filed 2026-05-14 | ||||
| 2024-12-31 | $4.68M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $9.15M derived: sum of 2 quarters · filed 2026-03-31 | $14.88M derived: sum of 3 quarters · filed 2026-03-31 | $20.88M 10-K · filed 2026-03-31 | ||||
| 2024-09-30 | $4.47M 10-Q · filed 2025-11-14 | $5.29M 10-Q · filed 2024-11-14 | $10.20M derived: sum of 2 quarters · filed 2025-11-14 | $16.20M 10-Q · filed 2025-11-14 | $18.64M 10-Q · filed 2024-11-14 | $18.45M derived: sum of 4 quarters · filed 2025-11-14 | ||
| 2024-06-30 | $5.73M 10-Q · filed 2025-08-14 | $6.54M 10-Q · filed 2024-08-13 | $11.73M 10-Q · filed 2025-08-14 | $13.36M 10-Q · filed 2024-08-13 | $13.98M derived: sum of 3 quarters · filed 2025-08-14 | $20.41M derived: sum of 4 quarters · filed 2025-08-14 | ||
| 2024-03-31 | $6.00M 10-Q · filed 2025-05-15 | $6.82M 10-Q · filed 2024-05-15 | $8.25M derived: sum of 2 quarters · filed 2025-05-15 | $14.68M derived: sum of 3 quarters · filed 2025-05-15 | $22.45M derived: sum of 4 quarters · filed 2025-05-15 | |||
| 2023-12-31 | $2.25M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $8.68M derived: sum of 2 quarters · filed 2025-03-31 | $16.44M derived: sum of 3 quarters · filed 2025-03-31 | $22.89M 10-K · filed 2025-03-31 | $26.66M 10-K · filed 2024-03-28 | |||
| 2023-09-30 | $6.43M 10-Q · filed 2024-11-14 | $14.20M derived: sum of 2 quarters · filed 2024-11-14 | $20.64M 10-Q · filed 2024-11-14 | $28.36M derived: sum of 4 quarters · filed 2024-11-14 | ||||
| 2023-06-30 | $7.77M 10-Q · filed 2024-08-13 | $14.22M 10-Q · filed 2024-08-13 | $21.93M derived: sum of 3 quarters · filed 2024-08-13 | $29.16M derived: sum of 4 quarters · filed 2024-08-13 | ||||
| 2023-03-31 | $6.45M 10-Q · filed 2024-05-15 | $14.17M derived: sum of 2 quarters · filed 2024-05-15 | $21.39M derived: sum of 3 quarters · filed 2024-05-15 | $29.02M derived: sum of 4 quarters · filed 2024-05-15 | ||||
| 2022-12-31 | $7.72M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $14.94M derived: sum of 2 quarters · filed 2024-03-28 | $22.57M derived: sum of 3 quarters · filed 2024-03-28 | $30.77M 10-K · filed 2024-03-28 | ||||
| 2022-09-30 | $7.22M 10-Q · filed 2023-11-14 | $14.85M derived: sum of 2 quarters · filed 2023-11-14 | $23.06M 10-Q · filed 2023-11-14 | $32.58M derived: sum of 4 quarters · filed 2023-11-14 | ||||
| 2022-06-30 | $7.63M 10-Q · filed 2023-08-14 | $15.84M 10-Q · filed 2023-08-14 | $25.36M derived: sum of 3 quarters · filed 2023-08-14 | $36.53M derived: sum of 4 quarters · filed 2023-08-14 | ||||
| 2022-03-31 | $8.20M 10-Q · filed 2023-05-15 | $17.73M derived: sum of 2 quarters · filed 2023-05-15 | $28.89M derived: sum of 3 quarters · filed 2023-05-15 | $36.38M derived: sum of 4 quarters · filed 2023-05-15 | ||||
| 2021-12-31 | $9.53M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $20.69M derived: sum of 2 quarters · filed 2023-03-31 | $28.18M derived: sum of 3 quarters · filed 2023-03-31 | $32.08M 10-K · filed 2023-03-31 | ||||
| 2021-09-30 | $11.17M 10-Q · filed 2022-11-14 | $18.65M derived: sum of 2 quarters · filed 2022-11-14 | $22.56M 10-Q · filed 2022-11-14 | $26.84M derived: sum of 4 quarters · filed 2022-11-14 | ||||
| 2021-06-30 | $7.48M 10-Q · filed 2022-08-11 | $11.39M 10-Q · filed 2022-08-11 | $15.67M derived: sum of 3 quarters · filed 2022-08-11 | $19.05M derived: sum of 4 quarters · filed 2022-08-11 | ||||
| 2021-03-31 | $3.91M 10-Q · filed 2022-05-12 | $8.19M derived: sum of 2 quarters · filed 2022-05-12 | $11.57M derived: sum of 3 quarters · filed 2022-05-12 | $14.69M derived: sum of 4 quarters · filed 2022-05-12 | ||||
| 2020-12-31 | $4.28M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | $7.66M derived: sum of 2 quarters · filed 2022-03-28 | $10.78M derived: sum of 3 quarters · filed 2022-03-28 | $14.59M 10-K · filed 2022-03-28 | ||||
| 2020-09-30 | $3.38M 10-Q · filed 2021-11-15 | $6.50M derived: sum of 2 quarters · filed 2021-11-15 | $10.31M 10-Q · filed 2021-11-15 | $13.87M derived: sum of 4 quarters · filed 2021-11-15 | ||||
| 2020-06-30 | $3.12M 10-Q · filed 2021-08-16 | $6.93M 10-Q · filed 2021-08-16 | $10.49M derived: sum of 3 quarters · filed 2021-08-16 | $13.20M derived: sum of 4 quarters · filed 2021-08-16 | ||||
| 2020-03-31 | $3.81M 10-Q · filed 2021-05-17 | $7.37M derived: sum of 2 quarters · filed 2021-05-17 | $10.07M derived: sum of 3 quarters · filed 2021-05-17 | $12.46M derived: sum of 4 quarters · filed 2021-05-17 | ||||
| 2019-12-31 | $3.56M derived: 10-K/A 12 month − 10-Q 9 month · filed 2021-04-09 | $6.26M derived: sum of 2 quarters · filed 2021-04-09 | $8.65M derived: sum of 3 quarters · filed 2021-04-09 | $10.53M 10-K/A · filed 2021-04-09 | ||||
| 2019-09-30 | $2.70M 10-Q · filed 2020-11-09 | $5.09M derived: sum of 2 quarters · filed 2020-11-09 | $6.97M 10-Q · filed 2020-11-09 | $8.55M derived: sum of 4 quarters · filed 2020-11-09 | ||||
| 2019-06-30 | $2.39M 10-Q · filed 2020-08-10 | $4.27M 10-Q · filed 2020-08-10 | $5.85M derived: sum of 3 quarters · filed 2020-08-10 | $7.25M derived: sum of 4 quarters · filed 2020-08-10 | ||||
| 2019-03-31 | $1.88M 10-Q · filed 2020-05-11 | $3.46M derived: sum of 2 quarters · filed 2020-05-11 | $4.87M derived: sum of 3 quarters · filed 2020-05-11 | |||||
| 2018-12-31 | $1.58M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | $2.98M derived: sum of 2 quarters · filed 2020-03-16 | $6.13M 10-K · filed 2020-03-16 | |||||
| 2018-09-30 | $1.41M 10-Q · filed 2019-11-12 | $4.55M 10-Q · filed 2019-11-12 | ||||||
| 2018-03-31 | $1.47M 10-Q · filed 2019-05-10 | |||||||
| 2017-12-31 | $3.66M 10-K · filed 2019-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |